Shenzhen Neptunus Interlong Bio-technique Full Year 2023 Earnings: EPS: CN¥0.014 (vs CN¥0.032 in FY 2022)

Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Full Year 2023 Results

Key Financial Results

• Revenue: CN¥1.06b (up 7.9% from FY 2022).
• Net income: CN¥24.1m (down 56% from FY 2022).
• Profit margin: 2.3% (down from 5.5% in FY 2022).
• EPS: CN¥0.014 (down from CN¥0.032 in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Shenzhen Neptunus Interlong Bio-technique shares are down 2.5% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Shenzhen Neptunus Interlong Bio-technique has 4 warning signs (and 1 which is concerning) we think you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.